First Coronavirus Vaccine May Have This Level of Effectiveness; FDA Revokes Emergency Use Authorization for Hydroxychloroquine

By Fox News. A recent article said the desperation to prop up economies struggling under the weight of COVID-19 could result in a weaker vaccine.

Although a “knock-out blow” vaccine would be ideal, early vaccines may carry limitations, said Robin Shattock, an Imperial College London professor leading development of an experimental shot, according to Bloomberg.

“Is that protection against infection?” Shattock told the news company. “Is it protection against illness? Is it protection against severe disease? It’s quite possible a vaccine that only protects against severe disease would be very useful.” . . .

“Vaccines need to protect against disease, not necessarily infection,” said Dennis Burton, an immunologist and vaccine researcher at Scripps Research in La Jolla, California. . .

“My guess would be that the day after someone gets immunized, they’re going to think, ‘I can go back to normal. Everything will be fine,’” said Michael Kinch, associate vice chancellor at Washington University in St. Louis. “They’re not going to necessarily realize that they might still be susceptible to infection.” (Read more from “First Coronavirus Vaccine May Have This Level of Effectiveness” HERE)

____________________________________________________

FDA Revokes Emergency Use Authorization for Chloroquine, Hydroxychloroquine

By Fox News. The U.S. Food and Drug Administration (FDA) on Monday revoked the emergency use authorization (EUA) for chloroquine and hydroxychloroquine donated to the Strategic National Stockpile to treat certain hospitalized coronavirus patients, according to a new statement.

The FDA decided the legal criteria for issuing an EUA were “no longer met.”

Further, the FDA determined, based on ongoing analysis of the EUA and emerging scientific data, that the two drugs are unlikely to be effective in treating COVID-19 for the authorized uses in the EUA. While the drugs are deemed generally safe when prescribed for patients with malaria or an autoimmune disease, little was otherwise known about the potential effects they had in COVID-19 patients.

“In light of ongoing serious cardiac adverse events and other potential serious side effects, the known and potential benefits of chloroquine and hydroxychloroquine no longer outweigh the known and potential risks for the authorized use,” according to an FDA press release issued on Monday. (Read more from “FDA Revokes Emergency Use Authorization for Chloroquine, Hydroxychloroquine” HERE)

Follow Joe Miller on Twitter HERE and Facebook HERE